Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.54 |
| ▸ | GRM6 | O15303 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.54 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459586 | 1.00 | GRM8 (0.54) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL8234490 | 0.84 | GRM8 (0.34) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL4459591 | 0.84 | GRM8 (0.34) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL6267086 | 0.84 | ALOX15 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL15863573 | 0.79 | GABRR1 (0.33) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL28723761 | 0.77 | CHRM2 (0.31) | GSRCYP1A2NFKB1TSHRCYP2C19 | |
| SCHEMBL2153254 | 0.77 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL19525766 | 0.77 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Glutamic Acid SCHEMBL21268582 | 0.74 | GRM8 (0.69) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL27005 | 0.74 | GSR (0.53) | GSRDPP4DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366809-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4397322-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | Tianjin Hengrui Medicine Co., Ltd. (CN) | 2024-07-10 | — | — | EP | disclosed |
| CN-117615795-A | Inhibitors of prostate specific membrane antigen and medical application thereof | 天津恒瑞医药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023030434-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | 天津恒瑞医药有限公司 | 2023-03-09 | — | — | WO | disclosed |
| EP-0919622-B1 | Surface expression of enzyme in gene directed prodrug therapy | CANCER RES CAMPAIGN TECH (GB) | 2009-02-18 | — | — | EP | disclosed |
| EP-0804413-B1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RES CAMPAIGN TECH (GB) | 2000-05-17 | — | — | EP | disclosed |
| US-6025340-A | Surface expression of enzyme in gene directed prodrug therapy | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-02-15 | — | — | US | disclosed |
| EP-0774005-B1 | SURFACE EXPRESSION OF ENZYME IN GENE DIRECTED PRODRUG THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-12-29 | — | — | EP | disclosed |
| EP-0876160-B1 | LIGAND DIRECTED ENZYME PRODRUG THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-6004550-A | GENE-DIRECTED ENZYME PRODRUG THERAPY WHICH COMPRISES A VECTOR WHICH ENCODES A CARBOXYPEPTIDASE WHICH IS EXPRESSED WITHIN A CELL AND A PRODRUG WHICH CAN BE CONVERTED INTO AN ACTIVE DRUG BY SAID CARBOXYPEPTIDASE; TREATMENT OF TUMORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| US-6005002-A | Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| EP-0919622-A2 | Surface expression of enzyme in gene directed prodrug therapy | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-06-02 | — | — | EP | disclosed |
| EP-0876160-A2 | LIGAND DIRECTED ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-11 | — | — | EP | disclosed |
| EP-0804413-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997026918-A2 | LIGAND DIRECTED ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-07-31 | — | — | WO | disclosed |
| EP-0774005-A1 | SURFACE EXPRESSION OF ENZYME IN GENE DIRECTED PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| EP-0772455-A2 | INTRACELLULAR EXPRESSION OF CARBOXYPEPTIDASE G2 IN ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996022277-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996003515-A2 | SURFACE EXPRESSION OF ENZYME IN GENE DIRECTED PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003151-A2 | INTRACELLULAR EXPRESSION OF CARBOXYPEPTIDASE G2 IN ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366809-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | KLK3, MAN2B2, ACP3 | GRM8 1814/4885GRM6 1835/4885GRIN2D 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.